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Abstract 
Multiple Sclerosis (MS) and Guillain-Barré Syndrome (GBS) are both demyelinating and 
autoimmune disorders affecting, respectively, the central nervous system (CNS) and the 
peripheral nervous system (PNS), which means they belong to a group of neurodegenerative 
diseases that involve inflammatory lesions associated with demyelination, inducing axonal 
damage and consequent neurodegeneration, leading to progressive loss of function.  
MS is a chronic inflammatory disorder of the CNS and is assumed to be the most frequent 
cause of neurological disability in young adults. This disorder consists in inflammation, 
demyelination and variable levels of axonal loss. The etiology is still unknown but it is 
presumed to involve interaction between genetic and environmental factors that triggers an 
autoimmune attack, resulting in damaged myelin and axons.  Clinically, most of the patients 
experience a relapsing-remitting phase, characterized by relapses followed by recovery. The 
majority of them, late on enter in a progressive phase called secondary progressive MS. The 
remaining patients pursue a progressive course that is called primary progressive MS. There is 
also clinically isolated syndrome corresponding to a first episode of neurologic symptoms in 
the CNS, and people who experience it may or may not develop MS. In terms of therapeutic 
options, disease-modifying treatments are approved specially to treat relapsing remitting form 
of the disease.  
GBS is also an inflammatory demyelinating disease of the PNS and it is the most frequent 
cause of acute flaccid paralysis. This autoimmune disorder is, in most cases, preceded by viral 
or bacterial infections, such as Campylobacter jejuni or Influenza virus, that are capable of 
triggering an abnormal immune responses directed against components of the peripheral nerves 
by molecular mimicry. Clinically, the most frequent forms of GBS is acute inflammatory 
demyelinating polyradiculoneuropathy and acute motor axonal neuropathy, but there is also 
acute motor-sensory axonal neuropathy and Miller-Fischer syndrome. Patients with GBS 
commonly have respiratory insufficiency and autonomic dysfunction as associated 
complications. The treatment of this syndrome is composed by a multidisciplinary approach 
that includes general medical care and immunotherapies.  
The priorities for MS and GBS investigation include establishment of biomarkers and an 
improved knowledge of the immunopathogenesis, to go towards personalized medicine.  
Keywords: Multiple Sclerosis, Guillain-Barré syndrome, Inflammation, Demyelination, 
Neurodegeneration. 
 
 
Resumo 
A Esclerose Múltipla (EM) e o Síndrome Guillain-Barré (SGB) são ambos doenças 
autoimunes e desmielinizantes que afetam, respetivamente, o Sistema Nervoso Central (SNC) 
e o Sistema Nervoso Periférico (SNP), pertencendo ainda a um grupo de doenças 
neurodegenerativas que envolvem lesões inflamatórias associadas a desmielinização, induzindo 
dano no axónio e consequente neurodegeneração, o que leva a uma perda de função progressiva.  
A EM é uma doença inflamatória crónica do SNC sendo a causa mais frequente de distúrbios 
neurológicos em jovens adultos. É uma doença que consiste na inflamação, desmielinização e 
uma variável perda axonal. A sua etiologia ainda não é completamente conhecida, mas 
presume-se que envolva a interação entre fatores genéticos e ambientais, estimulando um 
ataque autoimune e consequentes danos na mielina e nos axónios. Clinicamente, a maior parte 
dos doentes tem uma fase recidivante-remitente, caracterizada pela presença de surtos seguida 
de recuperação. Destes doentes, a maioria progride para uma doença secundária progressiva e 
os restantes doentes desenvolvem uma Esclerose Múltipla primária progressiva. Alguns doentes 
têm ainda um síndrome clinicamente isolado que corresponde a um primeiro episódio de 
sintomas neurológicos no SNC, sendo que estes podem ou não evoluir para Esclerose Múltipla. 
Em termos de tratamento, estão aprovados os medicamentos modificadores de doença, 
especialmente no caso de doença recidivante-remitente.  
A SGB é uma doença inflamatória, mas do SNP, sendo a causa mais frequente de paralisia 
flácida aguda. Esta doença autoimune é antecedida por uma infeção viral ou bacteriana, como 
vírus Influenza ou Campilobacter jejuni, que são capazes de desencadear uma resposta imune 
anormal direcionada contra os componentes dos nervos periféricos, por mimetismo molecular. 
As formas mais frequentes são polineuropatia desmielinizante inflamatória aguda e neuropatia 
motora axonal aguda, existindo ainda a neuropatia motora sensorial axonal aguda e a síndrome 
de Miller Fisher. Os doentes com SGB têm insuficiência respiratória e disfunção autónoma 
como complicações associadas. O tratamento é composto por uma abordagem multidisciplinar 
que inclui cuidados médicos gerais e imunoterapia.  
As prioridades na investigação da EM e da SGB incluem o desenvolvimento de 
biomarcadores e um melhor conhecimento da imunopatogénese, para que haja medicina 
personalizada.  
Palavras-chave: Esclerose Múltipla, Síndrome Guillain-Barré, Inflamação, 
Desmielinização, Neurodegeneração. 
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1. Introduction 
Multiple Sclerosis (MS) and Guillain-Barré Syndrome (GBS) are demyelinating diseases 
that affect, respectively, the central nervous system (CNS) and the peripheral nervous system 
(PNS), which means they belong to a group of neurodegenerative diseases that consists in 
inflammatory lesions associated with demyelination, inducing axonal damage, 
neurodegeneration and progressive loss of function (1). The term demyelination defines a 
pathologic process that implies destruction of myelin-supporting cells (oligodendrocytes in 
CNS and Schwan cells in PNS) and/or myelin sheath with some preservation of axons, and, 
therefore intrinsically normal myelin is destroyed (2). Central demyelination affects the CNS 
and peripheral demyelination involves the PNS, being that this division occurs depending on 
the site of the primary demyelination. 
MS is a chronic inflammatory and autoimmune disorder of the CNS and is assumed to be 
the most frequent cause of neurological disability in young adults, being that affects mostly 
young women. This disorder consists in inflammation, demyelination and variable levels of 
axonal loss. Although the etiology is unknown, it is presumed to involve interaction between 
genetic, environmental and other factors that triggers an aberrant autoimmune attack resulting 
in damaged myelin and axons (3,4).  Clinically, most of the patients (80-85%) experience a 
relapsing-remitting phase (RRMS), characterized by relapses and a functional recovery after 
that, but about 50% of RRMS patients enters in a progressive phase called secondary 
progressive MS (SPMS) after a variable period. The remaining 15-20% MS patients pursue a 
progressive course that is mentioned to as primary progressive MS (PPMS). There is also 
clinically isolated syndrome (CIS) corresponding to a first episode of neurologic symptoms in 
the CNS, and people who experience it may or may not develop MS (4). 
GBS is an inflammatory demyelinating disease of the PNS which is caused by abnormal 
immune responses targeted against components of the peripheral nerves (5), therefore it is also 
recognized as acute autoimmune peripheral neuropathy and is the most frequent cause of acute 
flaccid paralysis after the eradication of Poliomyelitis (6). It affects more men than women and 
it can occur at any age (2,7). This autoimmune disorder is, in most cases, preceded by viral or 
bacterial infections, for instance Cytomegalovirus, Epstein-Barr Virus (EBV) and Influenza 
virus, or Campylobacter jejuni and Mycoplasma pneumoniae (2).  Clinically, the most frequent 
form of GBS is acute inflammatory demyelinating polyradiculoneuropathy (AIDP), but there 
is also acute motor axonal neuropathy (AMAN), acute motor-sensory axonal neuropathy 
(AMSAN) and Miller-Fischer syndrome (MFS) (8). 
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In this review I will summarise the current information in terms of the immunopathogenesis, 
clinical course and characteristics as well as therapeutic approaches of both diseases. In the end 
I will present a comparison between MS and GBS. 
   
1.1. Aim  
The aim of this review is to compare MS and GBS considering the fact that they are both 
autoimmune and demyelinating diseases, but attacking different sites of the nervous system, by 
summarising the important differences between both diseases.  
 
2. Material and Methods 
The review was based on an exhaustive electronic and online research, using as keywords 
the following concepts: Multiple Sclerosis, Guillain-Barré Syndrome, Multiple Sclerosis and 
Guillain-Barré Syndrome, Demyelinating diseases, central and peripheral demyelinating 
diseases. The databases used were PubMed and Google Scholar and all the bibliographies in 
the reviews were read.  
 
3. Multiple Sclerosis 
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the CNS (9) affecting 
mostly young adults between 20 and 40 years old, with a female prevalence (10). The cause of 
MS is still unknown, but a multifactorial and heterogenous etiology is recognized, with a 
development of the disease in individuals with genetic susceptibility, who are exposed to 
various triggering environmental factors, for example Epstein-Barr virus and vitamin D (4,10). 
Pathologically, MS is described by inflammation, demyelination and axonal damage, with 
progressive neurodegeneration, caused by an autoimmune response to self-antigens, leading to 
loss of motor and sensory function (1,4,10–14), however immunopathogenesis is not 
completely known (15). Inflammation causes damage in the oligodendrocytes and 
demyelination, leading to neuronal damage (12). Additionally, the demyelinating lesion 
comprehends the immunologic response controlled by CD4 and CD8 T cells (9) and the 
involvement of B cells, that are also important in the pathogenesis of the disease (9). These 
lesions or plaques are commonly found in the optic nerves, brainstem, spinal cord and 
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cerebellum (16). In fact, disease progression might lead to permanent and irreversible disability 
and neuronal damage (12). 
MS generally includes three phases: a pre-clinical phase, where an association of 
environmental and genetic factors trigger the disease; a clinical phase, in which patients have 
initially a relapsing remitting MS (RRMS), with relapses and episodes of neurologic 
dysfunction; and a progressive phase, with worsening of the episodes (4,17). The progressive 
MS can develop from RRMS, and in this case, it is called secondary progressive MS (SPMS), 
or it can be progressive from the beginning, named primary progressive MS (PPMS) (17). 
Patients with MS can also experience Clinically Isolated Syndrome (CIS), that corresponds to 
the first clinical event in the CNS (3,4). Clinical symptoms are different depending on the 
location of neurologic lesions and are related to the invasion of inflammatory cells through 
blood-brain barrier (BBB) (11).  
The understanding of the immunopathogenesis of MS is important to contribute to the 
development of therapeutic options. In the past years, disease-modifying treatments were 
approved to treat MS, especially the relapsing remitting forms, with a possible decrease in the 
progression as well as an alteration in the course of the disease (3). However, there are few 
therapeutic options to treat progressive forms of the disease (17) and no options that promotes 
remyelination (9). 
 
3.1. Etiology of Multiple Sclerosis  
The etiology of MS is still unknown, although it is presumed to involve interaction between 
genetic and environmental factors that triggers an immune dysregulation. Even though MS is 
not an inherited disease, there are evidences showing a strong genetic factor (3): the risk of 
having MS among first-degree relatives of MS patient is 10-50 times higher than the general 
population with an absolute risk of 2-5% (18); genetic studies have revealed some gene loci as 
risk factors, being the major histocompatibility complex (MHC) HLA DR15/DQ6 allele the 
strongest one, but also the alleles of interleukin-2 receptor alpha gene (IL2RA) and interleukin-
7 receptor alpha gene (IL7RA) have been recognised as inheritable risk factors (18–20). 
Nevertheless, genetic susceptibility does not totally explain the etiology in MS, suggesting 
that environmental factors, such as Epstein-Barr virus infection and deficiency in vitamin D, 
have an important role in the risk of having MS (21,22). The incidence and prevalence of this 
disease, in regions of temperate climate, increase with latitude, both north and south of the 
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equator (21). In addition, there is an inverse correlation between MS risk and prevalence with 
sunlight exposure and vitamin D, which appears to have a protective effect and consequently 
help on reducing the risk of having MS (22). 
 
3.2. Multiple Sclerosis Pathogenesis and immunopathogenesis  
In MS, the innate and adaptative responses of the immune system are dysregulated, and it is 
thought that myelin reactive CD4+ T cells (T helper cells) and CD8+ T cells have a central role 
in the pathogenesis of this disease, with a contribution by B cells (3,15,17,23). In addition, it 
has been identified differences in the involvement of T lymphocytes specific to CNS antigens, 
activated macrophages and microglia, antibodies directed against CNS antigens and 
complement (15,24) (Figure 1). The immunological patterns in this disease, particularly, in early 
phases, are heterogeneous and patient dependent, leading to different pathogenic mechanisms 
and tissue targets (15,24). The diversity in the pathogenesis of demyelination is due to either 
models resembling an autoimmune antibody and T lymphocyte-mediated disorder directed 
against myelin, as well as oligodendropathy with consequent demyelination (24), whereas 
different susceptibility of target tissue has been found between subsets of patients, suggesting 
an interindividual disease heterogeneity (15,25).  
The CD4+ T cells are found in a variable number in perivascular and meningeal 
inflammatory infiltrates but in a lower quantity comparing to CD8+ T cells (26). There are 
studies indicating that Th-1 cells, which release proinflammatory cytokines, including IL-2 and 
TNF-α, are the crucial participants in mediating inflammation in MS, as well as Th-17 cells, 
releasing IL-17 (3,27). It is also thought that T helper cells induce the formation of  MS lesions 
due to recruitment of macrophages that consequently present antigens (26). CD8+T cells are 
also thought to be involved in the pathogenesis of MS by inducing axonal pathology by direct 
injury of neurons and oligodendrocytes (3). The involvement of B cells in this pathogenesis is 
probably through autoantibody secretion and antigen presentation to T cells, and it has been 
recognized recently due to observed pathological heterogeneity of lesions and the success of B 
cell-based immunotherapies (3). B cells and plasma cells are mostly present in the perivascular 
and meningeal inflammatory infiltrates (26), and, in patients with evident inflammatory 
pathology, large B cell aggregates may occur (26,28). Although the exact function of these cells 
is still uncertain, it is known that B cells specific for myelin, when into the CNS, can lead to 
demyelination via IgG deposition and complement-mediated mechanisms, nonetheless, this 
mechanism remains controversial. Instead, antibody-independent mechanisms that could affect 
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T cells responses, including MHC II dependent antigen presenting cell functions (29) as well 
as IL-6 production, can have a crucial role in the pathogenic function of B cell  (15).  
The peripheral activation and consequent migration of autoreactive Th1 and Th17 cells into 
the CNS is considered to be a crucial phase in the pathogenesis of MS (23,30). It is thought that 
this loss of peripheral tolerance can cause dysregulation in CD4+ T cell responses, leading to 
the pathogenicity of these cells (15,31) and can also conduce to the activation and development 
of B cells, leading to BBB disruption (32), followed by multifocal infiltration of immune cells, 
oligodendrocyte loss, reactive gliosis and consequent axonal degeneration and demyelination, 
causing MS (15,17,33). The demyelination occurs in white matter as well as in the cortical and 
grey matter (17). In the cortex, different types of lesions have been described based on the 
location of the plaques, including subpial, intracortical and leukocortical (34). Furthermore, 
cortical lesions present in early MS are normally inflammatory and related with cognitive 
impairment (3,35–37).  
 
 
 
 
 
 
 
 
 
 
Figure 1: Immunopathogenesis of MS. CNS antigens appear to be the expected targets of the 
autoimmune response. In genetically susceptible individuals, who are exposed to certain environmental 
factors, there is a dysregulation of the immune system with activation of autoreactive T cells, that 
migrate into the CNS, where they  may become reactivated by antigen-presenting cells presenting CNS 
autoantigens on major histocompatibility complex molecules to the invading T cells. The released 
autoantibodies, complement proteins and proinflammatory cytokines lead to loss of oligodendrocyte, 
causing consequent demyelination and axonal loss.  Abbreviations: Treg, regulatory T cell; NK cell, 
natural killer cell; IL, interleukin. From (27) 
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In the pathogenesis of MS plaques, it is thought that autoreactive myelin-specific 
lymphocytes are activated outside the CNS, cross the BBB by contact of integrins on the surface 
of lymphocytes with cell adhesion molecules on endothelial cells (38), leading to the formation 
of new inflammatory demyelinating lesions (26,39). This process requires interaction between 
very late antigen-4 (VLA-4) integrin, in T lymphocytes, and the vascular cell adhesion 
molecule-1 (VCAM-1), present on brain vascular endothelium (3,26,38,40). After entering in 
the CNS, the autoreactive peripherally activated T cells can be reactivated when crossing with 
the autoantigenic peptides in the brain parenchyma in the context of MHC II molecules 
expressed by local antigens presenting cell, including dendritic cells, macrophages and B cells. 
This triggers an inflammatory cascade, leading to the release of cytokines and chemokines, 
recruitment of additional inflammatory cells, like T cells, monocytes and B cells, as well as 
persistent activation of microglia and macrophages, causing myelin damage (14,41). 
Additionally, activation of CNS glial cells, such as microglia, results in continued inflammation 
even when there is no further infiltration of exogenous inflammatory cells (3). 
The plaques or lesions in MS are focal areas of demyelination in association with variable 
inflammation and axonal loss, that mainly affect the white matter of the brain, spinal cord, optic 
nerves, brainstem and also cerebral cortex including subpial regions (3,42). The inflammatory 
infiltrates that predominates in the parenchyma of these plaques are CD8+ T cells, showing a 
clonal development persisting over time, although in some cases these lymphocytes were found 
to be in contact with oligodendrocytes or axons (26). These plaques can be characterized as 
classic active, smoldering, chronic inactive, demyelinating in the grey matter and remyelinated 
(26). Active plaques are present in relapsing remitting disease and are described by myelin 
degradation with axonal preservation, the presence of numerous macrophages, and a significant 
number of T cells and variable number of meningeal and peripheral B cells, and in the lesions 
it is possible to find oligodendrocytes activated possibly reflecting early remyelination 
(3,26,43). In acute lesions, the entire plaque is occupied with perivascular inflammatory cells, 
including macrophages, T cells, some B cells and plasma cells (26,42). On the contrary, in 
chronic active lesion the myelin-containing macrophages are densely found at the edge of the 
lesion with an inactive core (26). Smoldering lesion, or slowly expanding lesions, are 
principally seen in patients with progressive disease (44), having the periphery with activated 
microglia and the centre of the lesion inactive (26). Additionally, this lesions includes some 
macrophages digesting myelin components at the edge and dispersed T cells, indicating an 
outgoing expansion into the adjacent normal appearing white matter, as well as an acute axonal 
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injury at the edge (26). Furthermore, microglia dystrophy has been identified due to the 
accumulation of iron, whereas remyelination is absent (26). Nevertheless, the driving force 
causing a constant expansion is still unknown (26). The chronic inactive lesions are found in 
long standing MS. These lesions normally have thin myelin sheaths at the edge indicating 
remyelination, and few macrophages and T cells are found mostly in the perivascular space. 
There is as well evident axonal damage, leading to axonal loss (26). Demyelinating lesions in 
the grey matter occur in the cortex and are expected to be found in chronic disease phases 
(26,45) and are related to cognitive impairments (26). These lesions can be sited subpially, 
intracortically or overlap with the white matter, termed compound plaques (26). Finally, 
remyelination of plaques occurs spontaneously but is regularly incomplete. Remyelination is 
mediated by oligodendrocyte precursor cells that migrate into the lesion during the process (42). 
Remyelination fibres are described by thin myelin sheaths and may possibly appear in the 
periphery of lesions or may also completely remyelinate a lesion, consequently termed as 
shadow plaque, that appear in patients with relapsing or progressive disease, and that can go 
through new demyelination (3,26). The area of remyelination differs between patients and 
appears to be more frequent in the early stage of the disease and in lesions with inflammation 
and macrophage activity (26). In addition, the repair capacity is determined by the lesion 
location, with periventricular lesions revealing less extensive remyelination (26).  
Inflammation is associated with demyelination and neurodegeneration in all forms of the 
disease, being more noticeable in acute and relapsing forms and showing also an association 
with T and B cell infiltrates (15,46). In cortical lesions, the molecular incidents that are 
responsible for demyelination and neurodegeneration are Th1 and Th17-mediated 
inflammation, microglia activation, oxidative stress and cell death (15,47). Consequently, 
besides the autoreactive T lymphocytes it can be assumed that other immune cells have an 
important part in the trigger of MS (15). 
Even though demyelination is the major characteristic of this pathology, early axonal injury 
and loss occur and may lead to disability progression (3). The exact mechanisms of myelin and 
axonal injury are not entirely understood, but are likely to embrace direct injury to myelin, 
oligodendrocytes and axons by both activated CD4+ and CD8+ T lymphocytes, microglia and 
macrophages, antibodies and complement, as well as the indirect effects of proinflammatory 
cytokines (3,48).  
Neurodegeneration is characterized by damaged axons, neurons and synapses, and it can 
occur in both early and late phases of MS (49). Axonal loss has been indicated to be the most 
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important factor for permanent motor disability in  this disease (50), with acute axonal damage 
being more evident in the active demyelinating lesions (26). The loss of myelin also lead to 
axonal damage due to the loss of trophic factors, as well as oxidative injury that directly damage 
the axons (26). In chronic lesions, the axons are significantly decreased, contributing to failure 
in remyelination (26).  
The most important event contributing to relapsing MS is the entry of immune cells in the 
CNS (51). Identical to disease beginning, relapses are described by combined Th1 and Th17 
immune responses, with B cells being the antigen-presenting cells (17,51). However, relapses 
are not processes in persistent development and growth due to the activation of protective 
counterregulatory mechanisms in response to inflammatory demyelination, leading to disease 
remission (15). To continue, remission is described by remyelination, possibly in the early 
disease phase (52). This process is characterized by myelin internalization, induction of 
peroxisome proliferator-activated receptor, conversion of proinflammatory macrophages to 
anti-inflammatory macrophages responsible by clearing the myelin debris and stimulating 
oligodendrocyte differentiation during remyelination of the CNS (15,53,54).  
The progressive phase of the disease is defined by the gradual development of pre-existence 
lesions, causing diffuse injury in cortical regions and in normal-appearing white matter (14). 
Cortical lesions are most pronounced in subpial cortical layers and are related to meningeal 
follicles that consist of T and B cells germinal centres as well as follicular dendritic cells. 
Throughout progression, demyelination and neurodegeneration are related to immune-
dependent and independent mechanisms (15,17). In immune-dependent way, an innate response 
is recognized and involves activated microglia and macrophages, B cells as well as activated T 
cells in meningeal follicles (55) and in the periphery (15,17,56). Additionally, disturbed axonal 
ion homeostasis, mitochondrial injury and iron accumulation, can also contribute to 
neurodegeneration by immune-independent mechanisms (15,17,55). The pathological aspects 
associated with progressive MS includes brain atrophy, which is linked to axonal loss, cortical 
demyelination, microglia activation and failure of remyelination (17). 
 
3.3. Multiple Sclerosis Clinical course  
MS signs and clinical symptoms vary depending on the area of the CNS affected, and may 
have the involvement of sensory, motor, visual, autonomic and brainstem pathways (26,57). 
The characteristics of MS includes optic neuritis, an inflammation in the optic nerve, Uhthoff’s 
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phenomenon, described as a momentary oscillation or worsening of symptoms in the presence 
of an increase in body temperature, and Lhermitte’s phenomenon, which is an atypical electric-
shock like impression through the spinal or limbs on neck flexion (13,57–59). Established on 
symptoms beginning and their evolution, there are different phenotypes of this disease: CIS, 
RRMS, SPMS and PPMS (3,10,57). The progression of this disease is described as a permanent 
deterioration of neurologic symptoms with new lesions. The majority of patients with this 
disease begins with a relapsing remitting disease, converting it later to a SPMS (26). In PPMS, 
the disease is characterized by a continuous deterioration from the onset with no recovery in 
neurological function (1). The pathogenic process leading to progression is thought to result 
from a continuing inflammatory reaction (26). Patients with MS may present limb weakness, 
ataxia, sensory disturbances, diplopia and neurogenic bowel and bladder, and, with the 
progression of disease, patients may also develop cognitive impairment, depression, sensory 
loss and pain (16).   
 CIS is the term used to describe the first clinical event of the disease that by definition is 
isolated in time or not proceeded by any neurologic episode, and it may affect the optic nerves, 
the brainstem or the spinal cord causing an optic neuritis, a brainstem syndrome or an 
incomplete myelitis, respectively (3,10,60,61). In CIS patients, the most critical predictor of 
having a second relapse is the presence of classic demyelination lesions on baseline brain or 
spinal cord. In addition, cerebrospinal fluid (CSF) abnormalities, for example the presence of 
positive oligoclonal bands, may have additional prognostic value in patients with CIS (3,10,62). 
Following the occurrence of a CIS, the risk of developing MS is increased by the presence of a 
large number of lesions in the white matter (13,61,63), as well as younger age at the begging of 
this syndrome (10,63). 
The typical form of MS is RRMS. This form of the disease is described by the development 
of relapses, characterized by discrete episodes of neurologic dysfunction due to focal areas of 
demyelination (58,64), followed by symptom recovery (10,42,57), with partial or complete 
remission between relapses (1). The disease has an asymptomatic period of undetermined 
duration that go before the initial presentation with an isolated syndrome. The majority of 
patients will continue to have relapses, either with complete remissions or with gradual 
accumulation of disability, that can lead to the development of other signs and symptoms due 
to irreversible CNS damage, particularly if the brainstem or spinal cord are involved 
(10,13,18,42). Through a severe exacerbation, inflammatory damage to myelin affects adjacent 
axons, leading to poor recovery and permanent disability (42).  
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SPMS may evolve from relapsing remitting disease (42), due to overlapping progressive 
axonal injury that exceed the capacity of the brain to compensate for further axonal loss 
(17,18,33,65). Also, at disease beginning, male sex, older age, polysymptomatic onset, 
sphincter and motor symptoms are predictors of the conversion to SPMS, whereas regular 
attacks of optic neuritis are predictor of lower probability of conversion to SPMS (18). There 
is gradually less inflammatory activity, with a decreasing number of new or no relapses and 
new or increasing lesions with progressive brain atrophy (18). Besides that, patients also present 
neurologic symptoms that progress over time, mostly gait loss, with or without superimposed 
relapses (3,10,66,67)   
PPMS is characterized by progressive evolution and accumulation of disability from the 
beginning (3,26) with minor or no relapses, and normally develops with a progressive 
myelopathy (3,68). Furthermore, these patients have a slow progressive neurologic incapacity 
from the start of the disease and the majority of them (80%) present with a gait disorder due to 
a spastic paraparesis, which may be associated with sensory symptoms and sphincter 
dysfunction (10,68). Unlike relapsing remitting form, in primary progressive men and women 
are equally affected and the disease tend to develop at an older age (42).  
 
3.4. Therapeutic approach 
The treatments for MS can be divided into three categories, including acute relapse 
management, disease-modifying treatments and symptomatic treatments (57). In the acute 
exacerbations, the primary difficulty is identifying an episode as a true relapse or an 
exacerbation due to an existing demyelination lesion (57,58). In both cases, the priority is to 
reject or treat any associated infection that can cause this disturbances (57). If the relapse is of 
moderate or worse severity, the appropriate treatment should be high dose of corticosteroids, 
particularly, methylprednisolone, that tend to reduce the duration of the relapse but do not 
significantly influence the long-term effect of the exacerbation (42,57). Plasma exchange is 
sometimes used, when the relapse is severe or rapidly progressive, as an adjunctive therapy or 
alone (57). Additionally, physiotherapy should begin early to improve recovery (57,58). 
 In the last few years an increasing number of disease-modifying treatments have appeared 
for treating relapsing MS (10,57,69), and all of them have proved to be effective in decreasing 
clinical disease activity, and consequently modify the course of MS (10). However, for each 
treatment there is its own risk-benefit profile (10) and the decision of changing therapies 
depends on criteria based on clinical and radiologic features (57). Nevertheless, the suggestion 
18 
 
is to start treatment as early as possible to influence the frequency of relapses, stabilize disease 
activity and minimize long-term disability (42,57).  
In CIS, disease-modifying treatments, particularly interferon beta and glatiramer acetate, 
have proven to be capable of delaying clinically definite MS by approximately 1 year (57). If 
injectable therapy begins before clinically definite MS, there may be progress in cognitive 
results (57). 
For the progressive form of MS, Ocrelizumab is the only disease-modifying treatment 
approved (70), except for those patients with secondary progressive disease with two or more 
relapses in 2 years and slow progression, that may benefit with beta-interferon-1b or glatiramer 
acetate (57). In patients with SPMS with rapidly progressing disease, intravenous mitoxantrone 
can be considered, but it is necessary a tight monitorization of the cardiac side effects and acute 
myelogenous leukaemia (57). Intravenous methylprednisolone pulsed therapy can also be 
considered, but long-term information are absent (57,58,71).  In fact, effective treatments for 
progressive MS will be based on the early treatment of inflammation to prevent development 
of compartmentalized inflammation in the CNS, as well as therapeutic agents capable of 
targeting the innate immune process in the brain and non-immune approaches that target 
neurodegeneration and axonal dysfunction (17).  
Patients with MS experiences significant and incapacitating symptoms, that includes fatigue, 
cognitive impairment, pain, spasticity and bladder dysfunction (57). However, not all symptoms 
have effective therapies, so the essential methods includes eliminate co-existent causes, handle 
with triggering factors and use available treatments rationally and insistently until relief is 
obtained (57,58,64). For example, paresthesia may react to antidepressants and anticonvulsants, 
fatigue may necessitate amantadine and CNS stimulants and bladder function may improve 
with anticholinergic and β-blockers (42). Additionally, spasticity, spasms and muscle cramp 
react to stretching and to antispasticity medicines, including baclofen, tizanidine, 
benzodiazepines and, if necessary, botulinum toxin can be injected into specific muscles. If 
generalized spasticity is refractory to other treatments, intrathecal baclofen should be 
considered (42). However, there are no therapeutic options to treat muscle weakness, so 
physiotherapy is of most importance (42). 
Immune modulatory therapy is responsible for reducing the activation and proliferation of 
immune cells and their passage into the CNS by increasing intrinsic suppressor activity or 
restricting the destruction caused by inflammatory processes (42). Consequently, the aim of 
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these therapies is to decrease the frequency of relapses, reduce the number of lesions and slow 
the disability progression (3). This disease-modifying treatments includes injectable medicines 
(interferon-beta and glatiramer acetate), monoclonal antibodies (natalizumab and 
alemtuzumab), oral medication (fingolimod, dimethyl fumarate and teriflunomide) and a 
chemotherapeutic agent (mitoxantrone and cladribine) (42). They can be divided into those of 
moderate efficacy, with a decrease in annualised relapse rate (ARR) of 30-50%, which includes 
interferons, glatiramer acetate, fingolimod, teriflunomide, and dimethyl fumarate, and those 
with higher efficacy, with a decrease in ARR of more than 50%, including alemtuzumab and 
natalizumab (57,69). Oral medications are presently considered second line because their safety 
profile is less favourable, due to an increased risk of serious side effects in patients with mild 
disease. This concern results from the possibility for prolonged immunosuppression to increase 
the risk of infections and other diseases as a result of different immune surveillance (3).  
Interferons are endogenous proteins implicated in immune responses against infectious 
agents. In MS, beta-interferons (IFN-β) are related to the maintenance of BBB, reducing the 
entry of T cells into the CNS, as well as modifying T and B cells function and changing the 
expression of cytokines (3). This treatment with antiproliferative and immunomodulatory 
effects (10,72) was the first treatment to establish a decrease in the number of relapses, as well 
as a reduction in the development of new lesions in the brain (10). Additionally, it may delay 
progression of the disease and increase survival in patients with relapsing remitting disease 
(11,73,74), since therapy with IFN-β in secondary progressive disease neglects to modify 
disease progression (11,75). There are 4 formulations of IFN-β approved: subcutaneous IFN-β 
1a and  IFN-β 1b, intramuscular IFN-β 1a and subcutaneous pegylated IFN-β 1a (10).  
Glatiramer acetate is a synthetic polymer composed by 4 amino acids, having a complex 
mechanism of action related to mimicking myelin basic protein, a autoantigen targeted by the 
T cells (3).  Glatiramer acetate prevent the formation of myelin reactive T cells and activating 
specific regulatory T cell expression and Th2 anti-inflammatory cytokine production (3). This 
treatment have showed efficacy in treating relapsing remitting disease, but have limited effects 
on the progression of disability (3,10,76).  
Natalizumab is a humanized monoclonal antibody directed against the alfa-4 subunit of the 
VLA-4 adhesion molecule, that is expressed on the surface of lymphocytes. This molecule 
prevent the interaction with VCAM-1 on endothelial cells, inhibiting the passage of 
lymphocytes into the CNS through BBB (3,10,77). Natalizumab has inhibitory effects on the 
inflammatory aspects of the disease, demonstrating a decrease of more than 65% in relapses in 
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2 years of treatment and about 90% suppression of new inflammatory lesions (11,78). The most 
serious side effect of this therapy is progressive multifocal leukoencephalopathy (PML), that 
results from an activation of the John Cunningham virus that will not be attacked by the immune 
system due to Natalizumab action (11,57). In addition, PML has also been observed in patients 
using fingolimod and dimethyl fumarate as oral therapies (3,57).  
Alemtuzumab is a humanized monoclonal antibody directed against the CD52 antigen 
present in the B and T cells, macrophages and monocytes. The biding of this antibody with 
CD52 antigen will cause a deep and prolonged decrease of the cells mentioned above (10,79). 
Ocrelizumab is a humanized anti-CD20  monoclonal antibody (17) that reduces B cells via 
antibody-dependent cell-mediated toxicity, leading to the decrease of side effects related to 
infusion (80,81). This therapy is the first to demonstrate efficacy in patients with PPMS, by 
reducing disability progression (80). 
Fingolimod was the first oral treatment approved for treating relapsing remitting disease. In 
vivo, it converts to an analogue of sphingosine, downregulating receptor 1 of sphingosine 1-
phosphate on lymphocytes and in the endothelium, thus blocking T lymphocytes in lymph 
nodes and preventing autoreactive lymphocytes to enter into the CNS (10,11,82). Consequently, 
this treatment supresses disease activity, with a reduction of 60% in relapses (11).  
Teriflunomide is an active metabolite of leflunomide (3), that express its mechanism of 
action by inhibiting dihydroorotate-dehydrogenase, a mitochondrial enzyme implicated in the 
synthesis of pyrimidines in rapidly dividing cells (3,83). In MS, the anti-inflammatory effect of 
Teriflunomide is mediated by diminishing the activity of proliferating T and B cells (3,10,84). 
Dimethyl fumarate is the latest oral therapy approved in MS treatment (3). It is a derivative 
from fumaric acid, with a mechanism of action not well-established, but it seems to have an 
immunomodulatory effect through cytokine modulation, as well as a neuroprotective effect by 
decreasing the oxidative cellular stress, and consequently reducing axonal damage 
(10,80,85,86).  
Mitoxantrone is a synthetic antineoplastic agent with immunomodulatory effects, including 
suppression of T and B cells as well as macrophage proliferation. This therapy demonstrated 
reduction of relapse frequency and disability in patients with worsening of both relapsing 
remitting and secondary progressive disease (3).  
Cladribine is a purine nucleoside, that suffers phosphorylation in cells, leading to nuclear 
accumulation and cell death, decreasing immune cells by lymphocyte apoptosis (17,70). This 
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therapy demonstrated reduction in ARR in RRMS, and consequently it is approved for this form 
of disease (17,70).  However it is still unknown if cladribine may have positive long-term 
effects on progression of the disease (70). 
 
4. Guillain-Barré Syndrome 
Guillain-Barré syndrome (GBS) is as an inflammatory polyneuropathy and an antibody-
mediated disease (87) characterized by an acute beginning, rapid progression, symmetric 
weakness, unstable gait and hyporeflexia or areflexia (7,88), and is the most common cause of 
acute flaccid paralysis (89). 
The cause of this syndrome is still unknown, but in the majority of cases it appear 1 or 2 
weeks after a respiratory or gastrointestinal infection or other immune stimulus, that triggers an 
autoimmune response directed to peripheral nerves and their spinal roots (7,90,91). The 
interaction between microbial and host factors that determines if and how the immune response 
is altered towards autoreactivity is not well understood, as well as the genetic and environmental 
factors that affect the patient’s susceptibility (7,90). However, it is known that molecular 
mimicry between microbial and nerve antigens is an important trigger to the development of 
this syndrome, especially in infections by Campylobacter jejuni (90). Additionally, the immune 
response is responsible for producing antibodies that crossreact with gangliosides of peripheral 
nerves, leading to nerve damage and impediment of nerve conduction (Figure 2) (89).   
The clinical course, as well as severity and outcomes of GBS can be very different (89). The 
most common forms of this syndrome include acute inflammatory demyelinating 
polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN) (89,92–94), acute motor-
sensory axonal neuropathy (AMSAN) and Miller Fisher syndrome (MFS) (87,89,95,96). Even 
though the clinical presentation of the axonal and demyelinating forms are similar, 
improvement from axonal form is delayed and incomplete (97). Patients with GBS have 
bilateral, symmetric and ascending weakness of the limbs, numbness and paresthesias (93). 
They may also have related comorbidities, including respiratory insufficiency, autonomic 
dysfunction, venous thromboembolisms and neuropathic pain (16).    
All patients with Guillain-Barre syndrome need careful monitoring and can benefit from 
general medical care and the early start of specific treatment (7,98), especially in patients with 
rapidly progressive weakness (90,99). The principal objective of treating patients with GBS is 
to decrease the duration of disease and minimize its severity (100).  
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4.1. GBS Etiology  
Since the eradication of poliomyelitis, GBS has become the most common cause of acute or 
subacute flaccid weakness in the world (7,87,90), being more frequent in men rather than 
women, and the incidence increases with age (89,101). The exact cause of this syndrome is 
uncertain, but the majority of cases appear 10 to 14 days after a respiratory or gastrointestinal 
infection or another immune stimulus (87,89,90) and around 70% of patients can recognize a 
preceding disease even if it is habitually benign and may be underestimated or ignored by the 
patient (7,87,89). Various infections have been associated with GBS including 
Cytomegalovirus, Mycoplasma pneumoniae, Epstein-Barr virus, Influenza A, Haemophilus 
influenzae, Enterovirus and Campylobacter jejuni (88,102). In  about 40% of patients it is 
possible to find antibodies against Campylobacter jejuni antigen, making it the most common 
pathogen associated with GBS  (7,87). In addition, Zika virus can also trigger GBS and it is 
considered to be one of the most common causes, being that weakness starts a few days after 
infection (87,103).  
Genetic and environmental factors that influence patients predisposition to develop the 
disease are still unknown (90,104). Furthermore, the geographical variety, regarding the 
incidence of the disease and its types in the world, is possibly related to differences in exposure 
to certain types of infections, in association with different genetic susceptibilities between 
individuals or groups of people living in different areas of the world (89). These differences 
might be linked to the development of a particular subtype of this syndrome as well as to the 
course and severity of the disease (89).  
 
4.2. GBS Pathogenesis and immunopathogenesis  
GBS is a post-infectious, immune-mediated nerve injury, presenting various phenotypes, 
comprehending, principally, AIDP, in which the immune-related injury disturbs the myelin 
sheath and related Schwann cells, and AMAN, in which the membranes of nerve axons 
(axolemma) are the main target, therefore the immunopathogenesis varies in each of these 
phenotypes (7,90,105). Even though both T-cells and B-cells play a role in the immune 
response, GBS is mostly an antibody-mediated disorder (7,87,89,105–107). In the 
demyelinating form of GBS, antigens, that are still not identified, are assumed to be responsible 
for complement activation myelin destruction and clean up by macrophages. In the axonal type 
and in MFS, specific gangliosides, GM1, GD1a and GQ1b, that are at nodal structures and 
roots, are targeted by immunoglobulins and share epitopes with the infectives agents (105).  
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Along with the characterization of AMAN came the understanding that the axons might be 
the main focus of injury by the autoimmune process. In patients with AMAN, there is a 
formation of biomarkers antibodies that crossreact with neuronal membrane gangliosides: 
GM1a, GM1b and GD1a (7,87,94,108). Not every antiganglioside antibodies are neurotoxic 
but the ones that bind to GM1 or GD1a gangliosides trigger myelin-destroying complement 
(105). These antibodies appear as a consequence of molecular mimicry between the 
lipooligosaccharide of the infective organism, C. jejuni, and the surface molecules on the motor 
axons. This theory is based on the resemblance that the epitopes on the surface of the infectious 
agent have with  the epitopes on the surface of the peripheral nerves, resulting in a crossreactive 
autoimmune response (2,87,101,105). IgG1 and IgG3 immunoglobulins bind with GM1 and 
GD1a gangliosides and to stimulate axon injury by complement activation, membrane attack 
complex formation, disappearance of voltage-gated sodium channels, detachment of paranodal 
myelin and nerve conduction failure. Thereby, macrophages can invade from the nodes into the 
periaxonal space, scavenging the injured axons (7,87,89,105,109). This immunological cascade 
disturbs the anatomical and physiological integrity of exposed nerve membranes in nerve 
terminals and nodes of Ranvier, producing a nerve conduction blockade that is either reversible, 
or in severe cases, resulting in extensive axonal degeneration with reduced recovery (90).  
The immunological mechanisms implicated in AIDP are less understood. First, a wide range 
of immune stimulants, including viruses and bacterial agents, can cause this disease, and 
secondly, specific antibody biomarkers are yet to be described (7,87,90,110). In fact, several 
anti-nerves autoantibodies targeted at both proteins and glycolipids could be responsible for 
AIDP immunopathology. Instead, nerve specific T cells, directed against unidentified antigens 
might play a more important role in AIDP than it is recognized now (90). Nerve glycolipids 
that are expressed in glial membrane and in myelin are the most important candidates as crucial 
antigens in AIDP (90,111). Besides being present in axonal membranes, certain gangliosides, 
including GM1 and GQ1b, are expressed in glial membranes at the node of Ranvier, where they 
might intervene in the paranodal demyelination that causes the pathophysiological 
characteristics of  AIDP (90,112). These unknown antibodies can bind to the surface of 
Schwann cells, activating complement and leading to membrane attack complex formation and 
consequent vesicular degeneration, resulting in invasion of myelin by macrophages (89,92). In 
severe cases, the axons can be also damaged as a secondary consequence of the toxic enzymes 
and radicals that are released by immune mediated inflammatory response directed against the 
myelin (92). 
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The pathology in the AMSAN is similar to the axonal type, with the same model of 
macrophage invasion of the perinodal space. Although, in this type, the dorsal and ventral roots 
are both affected (92). Additionally, there is the same lack of lymphocytic inflammation 
expected in an antibody-mediated pathogenesis (92). 
MFS is associated with antibodies against GD1b, GQ1b, GD3 and GT1a, which are related 
to ataxia and ophthalmoplegia (89,90,93,95,113). In this type, the macrophages clean up the 
axons fragments and come in from the nodes (105). Furthermore, there is an abnormality of 
sensory conduction that is characterized by the decrease in the amplitude of action-potential of 
the sensory nerve that return to normal with clinical improvement. This fact is consistent with 
sensory peripheral nerve demyelination or conduction failure along the axon, rather than axonal 
loss followed by regeneration (92).  
To summarize, it is important to know that antibodies anti-GM1 and anti-GQ1b bind to 
peripheral nerves and neuromuscular junctions (114,115) and antibodies anti-GD1 bind to the 
nodes of Ranvier, paranodal myelin and neuromuscular junction as well (115,116).  
A new area for studies, that appeared from Japanese GBS studies has exposed the concept 
that glycolipid domains, composed of multiple glycolipid and lipid components, can combine 
to create neoantigens that do not appear in any single molecule (117). Furthermore, these 
alleged anti-complex antibodies only bind heteromeric or multimeric lipid complexes and are 
hard to detect. They are found in certain cases of AMAN, however they might be commonly 
present, but yet unknown, in AIDP (90,118).  
The nodal area is replete with possible antigens, including glycolipids and proteins, and is 
extremely susceptible to pathological disturbances stimulated by antibody deposits, 
complement activation and macrophage recruitment. Consequently, nodal conduction block, 
with origin in glial or axon, can occur rapidly, but functionality can be repaired in short periods 
of time through local repair of damaged membranes. On the contrary, complete axonal damage 
(119), particularly if located close to the nerve roots and at a long distance from the innervation 
target, will be a perpetual irreversible injury because regeneration cannot successfully occur 
over long distances. Even if these considerations have clinical importance, expectation of how 
they might affect outcome in individual cases is difficult (90).  
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Figure 2: Immunopathogenesis of GBS. Molecular mimicry and antiganglioside antibodies. Infections 
Campylobacter jejuni, may trigger humoral immune and autoimmune responses, resulting in nerve 
damage and consequently the symptoms of GBS. Lipooligosaccharide on the C. jejuni outer membrane 
may stimulate the production of antibodies that crossreact with gangliosides, such as GM1 and GD1a 
on peripheral nerves. The antigens targeted in AMAN are located at or near the node of Ranvier. The 
antibodies anti-GM1 and anti-GD1a bind to the nodal axolemma, leading to complement activation and 
MAC formation, followed by disappearance of voltage-gated sodium channels, causing detachment of 
the paranodal myelin and consequent nerve conduction failure. Macrophages then invade from the nodes 
to the periaxonal space, scavenging the injured axons. The antigens targeted in AIDP are, apparently, 
found on the myelin sheath. The antibodies can activate complement, leading to the formation of the 
MAC on the outer surface of Schwann cells, initiation of vesicular degeneration, and consequent 
invasion of myelin by macrophages. Abbreviations: AIDP, acute inflammatory demyelinating 
polyneuropathy; AMAN, acute motor axonal neuropathy; APC, antigen-presenting cell; GBS, Guillain–
Barré syndrome; MAC, membrane attack complex. From  (89) 
 
 
4.3. GBS Clinical course  
GBS is described as a rapidly progressive and ascending flaccid paralysis, with diminished 
or absent reflexes (120). However, this syndrome is extremely distinct regarding the presence, 
distribution and extent of sensory symptoms, weakness, ataxia, pain, cranial nerves 
involvement, autonomic dysfunction and also the course of the disease (89). The nature of 
preceding infection and the selectivity of the antiganglioside antibodies is another factor 
essential to establish the subtype as well as the clinical course of GBS (89,90). In fact, poorer 
outcomes are associated with an older age, C. jejuni infection in the four weeks prior the disease 
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and elevated degree of incapacity associated with maximal weakness (7,90). Additionally, 
preceding infection by C. jejuni is the most common cause associated with AMAN (89,90,105). 
In classic GBS the principal symptom, in the majority of patients, is rapidly progressive 
bilateral weakness (88,98,121,122). This type of weakness is characterized as ascending, 
usually from the distal lower extremities, but can also start more proximally in the legs or arms. 
A small number of patients might present with paraparesis, that can persist through the course 
of the disease and other patients might present with cranial nerve involvement culminating in 
facial, oculomotor or bulbar weakness, as in MFS (7), which might afterwards extend to the 
extremities. Additionally, patients might, at first, have sensory signs, ataxia and characteristics 
of autonomic dysfunction. Another common sign, in approximately 30% of patients, that 
precedes weakness is muscle or radicular pain, usually but not always in the spinal region 
(7,90,123). The majority of patients have or develop decreased tendon reflexes in the affected 
members. These reflexes can firstly be normal, particularly in pure motor and axonal types of 
Guillain-Barré, or in a few cases the reflexes can be hyper-reflexive (90,124). Patients can have 
progression of weakness in 4 weeks, but most patients get to the maximum severity (nadir) 
within 2 weeks (90,125). Furthermore, some patients present with paraparesis that may continue 
through the course of the disease (7,126). In rare cases of subacute GBS, progression can last 
up to 6 weeks after beginning, and through this phase around 20-30% of patients develop 
complications, including respiratory failure necessitating ventilation in intensive care unit 
(90,125). Additional complications are aspiration pneumoniae and sepsis (7,98). Patients might 
also have signs or symptoms of autonomic dysfunction, that are more common in severe 
weakness and in patients with respiratory failure (98) and they include cardiac arrythmia 
(tachycardia, bradycardia or asystole), arterial hypertension or hypotension, abnormal 
hemodynamic responses to drugs, excessive sweating and gastrointestinal dysfunction 
(including gastroparesis, paralytic ileus and diarrhoea) (7,89,90,127). Symptoms as urinary 
retention and constipation are rare at the beginning of the disease but generally appear at the 
nadir of the disease (7,98). Some studies showed that patients affected by autonomic failure and 
dysfunction have the recovery of these signs and symptoms similarly to the improvement of 
motor function (127). 
The symptoms at the onset of typical GBS are pain, paresthesia, numbness and rapidly 
progressive bilateral limb weakness (90,99,128). In addition, patients usually exhibit “rubbery 
legs” or legs that tend to buckle, in the presence or not of numbness or tingling. The weakness 
begins in the distal lower extremities and continues upwards, in hours or days, until arms and 
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facial muscles become affected, resulting in bulbar weakness and respiratory problems (122). 
On the opposite, muscle weakness might start in the arms first, which means that is a descending 
type, or simultaneously in the arms and legs (7).  
The duration and severity of this disease is extremely distinct in patients and can range from 
mild or moderate weakness, from which patients recover spontaneously, to patients becoming 
quadriplegic and ventilator-dependent without signs of recovery. Eventually, all patients begin 
to recover, even though recovery could follow an extended course and result in severe and 
persistent disability (90).  
The AIDP type is a sensory motor form of this syndrome that sometimes is associated with 
cranial nerve involvement, autonomic dysfunction and pain (89,92). On the contrary, the 
AMAN form is a pure motor form, in which the axonal polyneuropathy has not the involvement 
of sensory symptoms and signs (87,89,94). Therefore, pure motor form can appear either in 
patients with AMAN or with AIDP (90). Cranial nerve involvement, in its turn, are less 
recurrent than in AIDP but patients may have autonomic dysfunction and pain (89,94). 
Abnormally, disease progresses more rapidly, and recovery is often prolonged, due to axonal 
degeneration (89). Nevertheless, patients with AMAN recover quickly, even from severe 
weakness (89). In fact, rapid recovery of children with AMAN is explained by the quick repair 
of nodal and paranodal conduction block (87). 
The AMSAN can be thought as a severe form of AMAN, however, not only the motor fibres 
are affected but also sensory fibres, leading to sensory deficits (89,92–94). In addition, in this 
type of neuropathy, it may be present a slower or incomplete improvement (87,129). 
Clinical presentation of MFS is remarkably different from classic Guillain Barré syndrome, 
in part due to the fact that patients present a triad of ophthalmoparesis or ophthalmoplegia, 
ataxia and areflexia (90,96,130), and in the majority of patients, diplopia is the presenting 
symptom (89,96). Patients with this syndrome normally have a good clinical outcome, even if 
is commonly associated with other cranial nerve involvement and can develop weakness of the 
limbs and respiratory failure as well, termed Miller Fisher-Guillain-Barré overlap syndrome 
(89,90,131). Additionally, some patients have lower brainstem involvement, including facial 
and pharyngeal fragility (87). The prognosis of this syndrome is positive, with patients 
improving in 1 to 2 months and having a completely recuperation after 6 months without 
specific treatment (87). 
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4.4. Therapeutic approach  
The treatment of GBS necessitates a multidisciplinary approach involving general medical 
care and immunological treatment (7,87,90), since this syndrome has an uncertain course with 
fast deterioration (105). It is necessary to carefully monitor respiratory, cardiac and 
hemodynamic functions to prevent or manage complications, such as respiratory failure, cardiac 
arrhythmias and hypotension and hypertension (7,87,90). Additionally, care should also be 
taken to guarantee prophylaxis for deep vein thrombosis and management for potential bladder 
or bowel dysfunction (90,123,132). Early initiation of physiotherapy and rehabilitation as well 
as psychosocial support is of major importance  (7,87,123,132). Pain management using either 
opioids or non-steroidal anti-inflammatory medicines for short-term treatment (7) or other 
pharmacologic agents such as gabapentin, pregabalin and low doses of tricyclic agents, should 
be considered to treat neuropathic pain (87).   
There is no specific treatment for this syndrome, but some therapies have been used to target 
the components of the immune response (7). Immunomodulatory treatments, principally in the 
form of intravenous immunoglobulin (IVIg) therapy and plasma exchange, have demonstrated 
to be successful in accelerating recovery and improving outcome, being both equally 
efficacious (7,87,90,99,133). Immunotherapy is usually initiated when patients are not able to 
walk 10 m without help (89,134,135). One of these approaches should be initiated as early as 
possible, after the diagnosis of GBS is defined and before irreversible nerve damage happens 
(7,87,90). 
Plasma exchange eliminates antibodies, complement components and other humoral 
mediators of inflammation (89,105,133,134) and may enhance T cell suppressor function, 
leading to rapid clinical improvement, reduced necessity for mechanical ventilation and quicker 
recovery (105). Plasma exchange is beneficial when started in the first 4 weeks after the 
beginning of weakness in patients incapable of walking unassisted, but the major effect is 
noticed when this therapy is initiated in the first 2 weeks (89,90,133,134). Additionally, the 
common regimen consists of 5 sessions of plasma exchange administered over 2 weeks 
(133,134). However, in mildly affected patients, who are able to walk, may improve more 
rapidly after 2 sessions than without therapy (89,90). 
The mechanism of action of IVIg is not completely known but is related to his pleiotropic 
immune modulatory effects, that may inhibit of Fc-mediated activation of macrophages, impede 
binding of antibodies to neural targets and complement activation, preventing more nerve 
damage (89,99,105,136). This treatment is effective in patients who are incapable of walking 
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unaided, when initiated in the first 2 weeks after the beginning of weakness (89,90,99,134). In 
patients with persistent worsening, there are no evidence demonstrating that a second course of 
IVIg is effective (7,87,90). Whether IVIg dose (2 g/kg) is more effective in rapid treatment 
administered in 2 days (1 g/kg per day) or administered in 5 days (0,4 g/kg per day) is not 
determined (89,90). However, it is known that the total dose of IVIg (2 g/kg), is as effective as 
a complete regimen of 5 plasma exchange sessions, administered over 2 weeks (89,137).  
Association of plasma exchange followed by IVIg has not demonstrated to be more effective 
than both in monotherapy (87,90). Over the years, IVIg treatment has become the preferred one 
because it has widespread availability, fewer associated complications and good tolerability, 
peripheral vein access and convenience of infusing at night and weekends, although IVIg 
therapy is more expensive than plasma exchange (7,87,90).   
Oral and intravenous steroids, in monotherapy or associated with IVIg or plasma exchange, 
have not demonstrated efficacy in patients with GBS (7,87,138). However, intravenous 
methylprednisolone associated with IVIg may accelerate improvement, in a short-term, but 
does not significantly affect the long-term outcome of the disease or neuropathic pain 
(105,136,139).  
There are approximately 10 % of patients with GBS (87), who will have worsening of 
weakness after an initial recovery or stabilisation, named treatment-related fluctuations 
(87,90,99,140,141). It normally occur in the first 2 months after treatment with plasma 
exchange or IVIg is initiated, and these patients may possibly have a prolonged autoimmune 
response, causing a persistent damage on the peripheral nerves (87,89,90). There are evidences 
that children receiving treatment with IVIg administered over 2 days have treatment-related 
fluctuations more frequently than those who receive treatment in 5 days, suggesting that a 
shorter treatment regimen is associated with an increased risk of developing a treatment-related 
fluctuations (89,90,128,136). These patients may require additional treatment with one more 
course of plasma exchange or IVIg, that have demonstrated to be beneficial with improvement 
of patients (87,89,90). 
The majority of studies were realized in patients with AIDP and is indeterminate if patients 
with AMAN should receive the same treatment, however it is recommended to treat them 
similarly (89,90,136). In patients with MFS no clinical trials have been done, however there are 
evidences demonstrating that patients treated with IVIg have an earlier recovery than those 
treated with plasma exchange or even those who did not received immunotherapy 
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(89,136,142,143). Nevertheless, almost all patients with MFS have a completely recovery, 
regardless of whether they were treated with immunotherapy  (143,144), so immunotherapy in 
these patients is suppressed (89,136). In Miller Fisher-Guillain-Barré overlap syndrome, 
patients may be extremely affected and, in these cases, treatment with plasma exchange and 
IVIg continues an option (89,136). 
Outcomes of GBS are improved with both IVIg or plasma exchange, however many patients 
persist disabled, developing severe weakness, with a long disease course, sometimes with 
incomplete recovery and experiencing persistent fatigue or chronic pain (90,115).  
A new approach for the treatment of GBS is being studied in clinical trials and is related to 
specific complement inhibition, since activated complement can lead to disruption of ion 
channels and nodal structures (101,115). Eculizumab is a humanized monoclonal antibody that 
binds with high affinity to the complement factor C5, blocking its cleavage to C5a and 
proinflammatory cytolytic C5b-9 complex (145,146), thus preventing the formation of 
membrane attack complex and nerve injury, presently in an animal model (6,90,136,145). This 
antibody was effective in a murine axonal model of GBS and demonstrated to be partially 
efficacious in a patient with severe disease (101,145). Consequently, complement-directed 
treatments are promising future treatments of GBS (101). 
 
5. Comparison between Multiple Sclerosis and Guillain-Barré syndrome 
MS and GBS are both complex demyelinating diseases, however MS is a chronic 
inflammatory disease that affects myelin of the CNS, whereas GBS is an inflammatory disease 
affecting myelin in the PNS (1,24). They are both characterized by inflammatory lesions and 
consequent demyelination, leading to axonal damage, neurodegeneration and progressive loss 
of function (1). The major difference in the demyelination process is the type of supporting 
cells affected, once that in the CNS there is the destruction of oligodendrocytes and in the PNS 
Schwann cells are the ones affected by the destruction of myelin (2). A detailed comparison 
may be observed in table 1.  
According to the etiology of the diseases, they are still unclear, but it is known that MS is 
present in susceptible genetic patients that develops the disease after exposure to various 
environmental factors, for instance EBV and vitamin D (4,10). On the other hand, GBS occurs, 
in most cases, after a respiratory or gastrointestinal infection, particularly by Campylobacter 
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jejuni, but the genetic or environmental factors that predispose the susceptibility of patients are 
unknown (7,90,91).  
Pathologically, MS is caused by an abnormal autoimmune response to self-antigens, whereas 
GBS is an autoimmune antibody-mediated disease, however, in both diseases the 
immunopathogenesis are not completely recognized (15). In the first one, inflammation is 
responsible for damaging the oligodendrocytes and, consequently, for demyelination (12), and 
in the demyelinating lesions immune response is controlled by CD4 and CD8 T cells with the 
involvement of B cells (9). In contrast, the development of GBS is due to the molecular mimicry 
between microbial and nerve antigens, that triggers an immune response responsible for 
producing antibodies that crossreact with gangliosides of the peripheral nerves (89,90). 
Nevertheless, the ultimate consequence is the same for MS and GBS, demyelination is 
responsible for axonal and nerve damage, leading to neurodegeneration and progressive loss of 
function (1,4,7).  
In MS, after the triggering of the disease, patients will experience a  relapsing remitting 
clinical phase, with relapses and episodes of neurologic dysfunction, such as disturbances in 
sensory, motor or cerebellar function, followed by recovery, and lastly a progressive clinical 
phase, that can be divided in secondary and primary progressive with worsening of neurologic 
dysfunction, affecting, particularly the patient gait  (4,17). Patients can also have CIS, 
corresponding to the first episode of neurologic symptoms in the CNS, and they can develop 
MS (4). The clinical signs and symptoms of MS are different depending on the location of 
neurologic lesions (11), and may involve sensory, motor, visual, autonomic and brainstem 
pathways (26,57). The patients may experience optic neuritis, limb weakness, ataxia, sensory 
disturbances, diplopia and neurogenic bowel and bladder, and, with the progression of disease, 
patients may also develop cognitive impairment, depression, sensory loss and pain (16).  In 
GBS, the clinical course, severity and outcomes can be very different (89) depending on the 
patient´s form of disease, being the most common AIDP, AMAN, AMSAN and MFS (87,89). 
However, in all forms, the disease is characterized by an acute beginning, rapid progression, 
symmetric weakness, unstable gait and hyporeflexia or areflexia (7,88). The clinical 
presentation of the axonal and demyelinating forms are similar (97) and patients with GBS 
experiences bilateral, symmetric and ascending weakness of the limbs, numbness and 
paresthesias (93), as well as related comorbidities, including respiratory insufficiency, 
autonomic dysfunction, venous thromboembolisms and neuropathic pain (16).  
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In terms of therapeutic approach, MS is mostly treated with disease-modifying treatments to 
decrease disease progression and to modify the course of MS, whereas in GBS patients benefits 
from an association of general medical care and specific treatment with IVIg or plasma 
exchange (7,98), with the aim of to reduce the duration of disease and minimize its severity 
(100).  
 
6. Conclusions and Future perspectives  
MS is a complex disease with high heterogeneity, influenced by genetic and environmental 
factors as well as both innate and adaptative immune system. However huge progresses have 
been made in understanding MS and leading to the characterization of its immunopathogenesis, 
etiology and clinical course, as well as the discovery of disease-modifying therapies. Despite 
these advances, there are no immune or biochemical marker capable of precisely reflect disease 
pathogenesis, differentiate different phenotypes of the disease, serving as a control of disease 
activity or even predicting the future course of MS.  
Table 1: Comparison between MS and GBS 
Characteristics Multiple Sclerosis Guillain-Barré Syndrome 
Location and type 
Chronic disease of the CNS, 
affecting oligodendrocytes. 
Acute disease of the PNS, 
affecting Schwann cells. 
Etiology 
Association between genetic 
susceptibility and exposure to 
environmental factors. 
Preceded by respiratory or 
gastrointestinal infection. 
Immunopathogenesis 
Autoimmune response to self-
antigens, against 
oligodendrocytes and  
controlled by CD4 and CD8 T 
cells with involvement of B 
cells. 
Autoimmune antibody-
mediated disease, due to 
molecular mimicry between 
microbial and nerve antigens, 
with production of antibodies 
that crossreact with 
gangliosides. 
Clinical course 
Includes RRMS, SPMS, 
PPMS and CIS. 
Includes AIDP, AMAN, 
AMSAN, MFS. 
Therapeutic approach Disease-modifying treatments. 
General medical care and 
treatment with IVIg or plasma 
exchange. 
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With the development of new treatments, we are going towards to a more personalized 
medicine, where the therapeutic approach may be different for each patient and, if possible, 
based on genetic biomarkers. However, balancing benefits and safety of these therapies remains 
a challenge because serious side effects are associated with more effective therapies. Presently, 
one of the most important questions is how to better understand and treat progressive MS, and 
it may possible be based on therapeutic agents that can prevent or minimize both neuronal and 
axonal degeneration but capable of target compartmentalized processes in the CNS. Knowing 
the different mechanisms and immunopathological patterns of MS through disease course, is 
crucial to identify possible strategies to repair myelin and axonal structures, making possible 
the investigation and discovery of new therapeutic agents capable of targeting remyelination, 
with preservation of axons and oligodendrocytes. Additional studies are required to identify the 
different involvement of the various immune cells as well as the influence of environmental 
factors on the immune responses, with the aim of improving therapeutic approaches.  
GBS is, similarly, a heterogeneous disease, making it a difficult syndrome to study. 
Nevertheless, considerable progresses in understanding the nature of the disease and its 
mechanisms were made, although more studies are needed to completely comprehend its 
etiology, including the triggering events and patient-related factors that lead to GBS, its 
immunopathogenesis and to allow the development of biomarkers that can predict both the 
clinical course and the outcome of patients. Although there is now a great knowledge about the 
immunopathogenesis of GBS further research is required, especially on the AIDP form of the 
disease, that remains unclear, since most patients are seronegative for anti-ganglioside 
antibodies and it is still unknown if these patients express an unidentified autoantibody or if its 
immunopathogenesis is completely different. 
Treatment of GBS can be challenging due to different outcomes and severity in various 
cases. Therefore, it is important to develop more specific and effective therapies that can be 
personalised to each patient, considering patient’s possible biomarkers. Additionally, general 
medical care also needs to be improved to prevent or treat disease-related complications. 
Furthermore, prevention of severe axonal injury prematurely in the course of the disease 
continues to be a major focus, once it is an important restricting factor in accomplishing a great 
and long-term outcome.  
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